×

Analyst: Definite 1- to 2-year setback for Bristol

3:16 PM ET Fri, 5 Aug 2016

Shares of Bristol-Myers Squibb drop on a failed drug trial. Damien Conover, Morningstar equity analyst, discusses his views on the future Bristol-Myers.